Xediton Pharmaceuticals Inc. ("Xediton") Announced Today the Canadian Approval and Availability of Vabomere(r) (Meropenem-Vaborbactam) in Canada

Oakville, Ontario--(Newsfile Corp. - June 12, 2025) - Xediton Pharmaceuticals Inc. is proud to announce that Vabomere® (meropenem-vaborbactam) has been approved by Health Canada and is now commercially available across the country.

Vabomere is indicated in adults for the treatment of complicated urinary tract infections including pyelonephritis, complicated intra-abdominal infection, hospital acquired pneumonia including ventilator associated pneumonia, bacteremia and other infections with limited treatment options known or suspected to be caused by susceptible microorganisms, including KPC-producing CRE—one of the most critical AMR threats identified by Health Canada and the World Health Organization.

"The launch of Vabomere® in Canada marks a significant milestone for our company, patients and healthcare practitioners," said George Gafrey, President of Xediton Pharmaceuticals. This therapy provides physicians with a much-needed tool to treat life-threatening infections caused by organisms that are increasingly difficult to manage. We are proud of the collaborative effort by the Melinta and Xediton teams to make the product available, and we are committed to ensuring it reaches those who need it most."

"We are thrilled that VABOMERE is now readily accessible to patients in Canada," said Christine Ann Miller, President and Chief Executive Officer at Melinta. We are pleased to be able to partner with Xediton Pharmaceuticals in support of the registration and commercializing of VABOMERE in Canada, continuing to deliver on Melinta's commitment of ensuring that all people who need our life-saving therapies can get them."

Vabomere combines meropenem, a trusted broad-spectrum carbapenem, with vaborbactam, a novel β-lactamase inhibitor.

The approval is supported by data from TANGO II, a global Phase III clinical trial demonstrating improved clinical cure rates and survival compared to best available therapy in patients with CRE infections.

Vabomere reflects Xediton Pharma's commitment to supporting antimicrobial stewardship and advancing therapies that protect patients and preserve the power of antibiotics.

About Vabomere®

VABOMERE is an antibacterial combination product for intravenous infusion containing meropenem (a trusted carbapenem) and vaborbactam (a novel beta-lactamase inhibitor). VABOMERE is indicated in adults for the treatment of the following infections known or suspected to be caused by carbapenem-resistant, vaborbactam/meropenem-susceptible Gram-negative bacteria: